Abstract
Policy interventions to reduce climate impacts are being increasingly considered by healthcare decision-makers in many countries, such as the National Health Service in England and Ministero della transizione ecologica in Italy. Dry powder inhalers (DPIs) for the treatment of asthma demonstrated significantly lower greenhouse gas emissions than pressurised metered-dose inhalers. An analysis was conducted to estimate the reduction in carbon dioxide equivalent (CO2e) emissions related to once-daily indacaterol acetate/mometasone furoate (IND/MF) and once-daily indacaterol acetate/mometasone furoate/glycopyrronium bromide (IND/GLY/MF), delivered using Breezhaler® DPI device, compared to existing inhalers in the UK and Italy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
